Browsing Tag
Ventyx Biosciences
2 posts
Lilly to acquire Ventyx Biosciences (Nasdaq: VTYX) in a high-conviction bet on oral inflammation therapies
Eli Lilly is acquiring Ventyx Biosciences for $1.2B to advance oral inflammation therapies. Find out what this means for biotech M&A and chronic care strategy.
January 8, 2026
Ventyx Biosciences announces positive Phase 2 trial data for VTX3232 in obesity and cardiometabolic risk
Find out how Ventyx Biosciences’ VTX3232 is reshaping the obesity and cardiometabolic space through inflammation-targeted innovation.
October 23, 2025